A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,201–2,300 of 3,967
POINT: Do Randomized Controlled Trials Ignore Needed Patient Populations? Yes
Courtright, K. (2016) · Chest · doi:10.1016/j.chest.2016.01.029 · Cited by 9
Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
Murray, L. A., Grainge, C., Wark, P. A. B., & Knight, D. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.003 · Cited by 12
Toward Early Identification of Clinically Relevant Interstitial Lung Disease
Salisbury, M. L., & Lynch, D. A. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1235ed · Cited by 9
Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?
Maher, T. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1939ed · Cited by 9
Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10
Akter, T., Atanelishvili, I., Noguchi, A., Silver, R. M., & Bogatkevich, G. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188588 · Cited by 9
Takeda, T., Takeuchi, M., Saitoh, M., & Takeda, S. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.245.107 · Cited by 9
“Its effect on retarding disease progression has been demonstrated in 2 randomized trials; CAPACITY-004 trial (Noble et al. 2011) and ASCEND trial (King et al. 2014).”
BackgroundResultThe pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.
Kinoshita, Y., Ishii, H., Nabeshima, K., & Watanabe, K. (2021) · PubMed · doi:10.14670/hh-18-289 · Cited by 16
Managing interstitial lung disease detected on CT during lung cancer screening
Southern, B. D., Scheraga, R. G., & Yadav, R. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.14157 · Cited by 9
Kim, H., Yoon, S. H., Hong, H., Hahn, S., & Goo, J. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-34230-z · Cited by 10
Huang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01559-7 · Cited by 10
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?
Goodwin, A. T., Noble, P. W., & Tatler, A. L. (2022) · European Respiratory Journal · doi:10.1183/13993003.01748-2022 · Cited by 7
Self-citationNeutrophil extracellular traps linked to idiopathic pulmonary fibrosis severity and survivalPreprint
Matson, S. M., Ngo, L. T., Sugawara, Y., Fernando, V., Lugo, C., Azeem, I., Harrison, A., Alsup, A., Nissen, E., Koestler, D. C., et al. (2024) · medRxiv · doi:10.1101/2024.01.24.24301742 · Cited by 9
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
Astor, T. L., Goldberg, H. J., Snyder, L. D., Courtwright, A., Hachem, R., Pena, T., Zaffiri, L., Criner, G. J., Budev, M. M., Thaniyavarn, T., et al. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231165912 · Cited by 8
Lee, H., Jeong, O.-Y., Park, H. J., Lee, S., Bok, E., Kim, M., Suh, Y. S., Cheon, Y., Kim, H. O., Kim, S., et al. (2023) · Immune Network · doi:10.4110/in.2023.23.e45 · Cited by 8
Barth, S. E., Edwards, C. C., Saini, G., Haider, Y., Williams, N., Storrar, W., Jenkins, G. R., Stewart, I. D., & Wickremasinghe, M. I. Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02787-1 · Cited by 15
Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
Liu, J., Wang, F., Hong, Y., & Luo, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29266 · Cited by 8
Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis
Xu, H., Hui, S. L., Lee, J. S., Zhang, Z., & Boente, R. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1054oc · Cited by 10
Ma, J., Ding, L., Zang, X., Wei, R., Yang, Y., Zhang, W., Su, H., Li, X., Li, M., Sun, J., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1437231 · Cited by 9
Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents
D’Agnano, V., Perrotta, F., Fomez, R., Carrozzo, V. M., Schiattarella, A., Zamparelli, S. S., Pagliaro, R., Bianco, A., & Mariniello, D. F. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111391 · Cited by 12
“Pirfenidone, an antifibrotic and anti-inflammatory agent capable of inhibiting fibroblast proliferation and collagen deposition by targeting the TGF-β pathway, has gained approval for the treatment of IPF with a recommended full oral dosage of 2403 mg/day divided into three doses [8].”
Fibroblast Heterogeneity in Inflammatory Bowel Disease
Ke, B.-J., Dragoni, G., & Matteoli, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313008 · Cited by 9
Yu, D., Zhang, R., Zhou, J., Guo, P., Li, P., Ye, M., Liu, Y., & Shi, S. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.11.020 · Cited by 8
Kattih, Z., Kim, H. C., Aryal, S., & Nathan, S. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062029 · Cited by 9
“Fibrotic lung disease should be addressed with consideration for the institution of an antifibrotic therapy [61,62].”
Self-citationSu, Q., Feng, Y., Guo, J., Cui, X., Zhu, J., Yang, J., & Zhang, S. (2025) · Clinical & Experimental Immunology · doi:10.1093/cei/uxaf019 · Cited by 10
Zhou, J., Zhou, J., Wang, Y., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06786 · Cited by 8
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis
Chen, X., Wu, C. F., Tang, F., Zhou, J., Mo, L., Li, Y., & He, J. (2025) · Advanced Science · doi:10.1002/advs.202505067 · Cited by 15
Maher, T. M., Song, J. W., Kramer, M. R., LANCASTER, L. H., Corte, T. J., Yun, J. H., Kim, K., Cho, J., Sather, L., George, P. M., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003038 · Cited by 12
Self-citationEngelbrecht, E., Kooistra, T., Burg, N. D., Hariri, L. P., Nguyen, T. H., Brazee, P. L., Hla, T., Gochuico, B. R., & Knipe, R. S. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70102 · Cited by 15
Mechanisms on How Matricellular Microenvironments Sustain Idiopathic Pulmonary Fibrosis
Jones, N., Rahar, B., Bernau, K., Schulte, J. J., Campagnola, P. J., & Brasier, A. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115393 · Cited by 11
“Currently, IPF management involves supportive care, oxygen supplementation, a reduction in risk factors and use of approved anti-fibrotic therapy, such as Nintedanib and Pirfenidone [13–15].”
Lu, Q., Ye, C., Mao, W., Zeng, F., Liu, Z., Chen, R., Cheng, X., Gao, Y., Wang, M., Liu, M., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c04686 · Cited by 11
Monteleone, G., Passantino, L., Simonetti, J., Iovene, B., Varone, F., Cameli, P., Sgalla, G., & Richeldi, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145100 · Cited by 9
Callahan, S. J., Scholand, M. B., Kalra, A., Muelly, M. C., & Reicher, J. J. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.021 · Cited by 8
Meersseman, C., Martínez-Besteiro, E., Romain‐Scelle, N., Crestani, B., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Borie, R., Diesler, R., Valenzuela, C., et al. (2025) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2025.10.004 · Cited by 11
Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis
Hujjat, S. F. Z., Chandani, H. K., Chandani, D. K., Khan, M. S., & Mahmoud, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004290 · Cited by 13
The Patient Journey in Interstitial Lung Disease: Mobility, Independence, and Psychological Burden
Krauss, E., Tello, S., Kuhlewey, D., Mahavadi, P., Scharmer, C., Behr, J., Günther, A., & Huss, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248697 · Cited by 9
“Although antifibrotic therapies such as pirfenidone and nintedanib have fundamentally altered the course of fibrotic ILDs by slowing decline in lung function and improving survival, the lived burden remains profound [9,10].”
Operationalizing Chronic Inflammation: An Endotype-to-Care Framework for Precision and Equity
Ramos‐Niño, M. E. (2025) · Clinics and Practice · doi:10.3390/clinpract15120233 · Cited by 9
Adams, G. L., & Hayes, W. (2025) · Pharmaceutical Sciences and Drug Design · doi:10.51847/ie5dkk27c3 · Cited by 8
CD248/Endosialin: A Novel Pericyte Target in Renal Fibrosis
Chang-Panesso, M., & Humphreys, B. D. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000440890 · Cited by 8
Systemic sclerosis-associated interstitial lung disease
Scallan, C. J., Collins, B. F., & Raghu, G. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000707 · Cited by 12
Merino, A. M., Hoogduijn, M. J., Molina‐Molina, M., Arias‐Salgado, E. G., Korevaar, S. S., Baan, C. C., & Montes‐Worboys, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248415 · Cited by 9
Antifibrotics and lung transplantation: A Spanish multicentre case‐controlled study
Cuesta, V. M. M., Fernandez, D. I., Ibáñez, S. A., Anguera, G., Iribarnegaray, J. M., Hernández-Rubio, J. C., Mezquida, J. P. R., Pérez-González, V. L., Hernández, R. L., Gafas, A. D. P., et al. (2022) · Respirology · doi:10.1111/resp.14352 · Cited by 9
Perrotta, F., Chino, V., Allocca, V., D’Agnano, V., Bortolotto, C., Bianco, A., Corsico, A. G., & Stella, G. M. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2145948 · Cited by 9
Cottin, V., Spagnolo, P., Bonniaud, P., Dalon, F., Nolin, M., Kirchgässler, K.-U., Ganse, E. H. V., & Belhassen, M. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100951 · Cited by 9
Connective Tissue Disease Associated Interstitial Lung Disease
Matson, S. M., & Demoruelle, M. K. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.005 · Cited by 11
Farrand, E. D., Collard, H. R., Guarnieri, M., Minowada, G., Block, L., Lee, M., & Iribarren, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280342 · Cited by 8
Swaminathan, A. C., Snyder, L. D., Hong, H., Stevens, S. R., Long, A. S., Yanchenko, E., Qiu, Y., Liu, R., Zhang, H., Fischer, A., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202210-1947oc · Cited by 8
Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016–2022
Shankar, D. A., Hawkins, F. J., Alysandratos, K., Wilson, K. C., Walkey, A. J., Bosch, N. A., & Law, A. C. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202308-697rl · Cited by 8
Neighborhood Health and Outcomes in Idiopathic Pulmonary Fibrosis
DeDent, A. M., Collard, H. R., & Thakur, N. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202304-323oc · Cited by 9
Pulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face
Mendoza‐Marí, Y., Fraix, M. P., & Agrawal, D. K. (2024) · Archives of Internal Medicine Research · doi:10.26502/aimr.0165 · Cited by 16
Enzel, D., Kriventsov, M. A., Sataieva, T., & Malygina, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168946 · Cited by 12
Trujillo, G., Regueiro‐Ren, A., Liu, C., Hu, B., Sun, Y. S., Ahangari, F., Fiorini, V., Ishikawa, G., Jumaily, K. A., Khoury, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0065oc · Cited by 13
Petersen, A. G., Korntner, S. H., Bousamaki, J., Oró, D., Manresa-Arraut, A., Pors, S. E., Salinas, C. G., Andersen, M. W., Madsen, M. R., Nie, Y., et al. (2024) · Physiological Reports · doi:10.14814/phy2.70077 · Cited by 7
Tang, D. T. Y., Du, Z., Yang, K. S., Bestvater, B. P., Kaplan, J. A., Neubig, M. E., Olen, C. L., Phillips, B., Wang, P., Hudson, T. E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02090 · Cited by 8
Enomoto, N., Chida, K., Suda, T., Kaida, Y., Taniguchi, M., Azuma, A., Hayashi, H., Ogura, T., Kitamura, H., Yamaguchi, O., et al. (2015) · The Clinical Respiratory Journal · doi:10.1111/crj.12281 · Cited by 8
Rare (pulmonary) disease day: “feeding the breath, energy for life!”
Harari, S. A., Lau, E., Tamura, Y., Cottin, V., Simonneau, G., & Humbert, M. J. C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00221914 · Cited by 8
Vigeland, C. L., Collins, S. L., Chan‐Li, Y., Hughes, A. H., Oh, M. H., Powell, J. D., & Horton, M. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163288 · Cited by 10
Ward, K., Spurr, L., Goldman, N. R., et al. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.10.007 · Cited by 8
Safety of IV Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis
LIMPER, A. H. (2017) · CHEST Journal · doi:10.1016/j.chest.2016.12.015 · Cited by 8
Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
Lyseng-Williamson, K. A. (2017) · Drugs & Therapy Perspectives · doi:10.1007/s40267-017-0459-x · Cited by 11
Clinical Trials in Idiopathic Pulmonary Fibrosis in the “Posttreatment Era”
Gibson, K. F., & Kass, D. J. (2018) · JAMA · doi:10.1001/jama.2018.6225 · Cited by 8
Futuro del tratamiento farmacológico en fibrosis pulmonar idiopática
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.05.008 · Cited by 10
Interstitial Pneumonia with Autoimmune Features
Fischer, A. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.05.007 · Cited by 9
George, P. M., & Mitchell, J. A. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00330.2019 · Cited by 9
The future of pharmacological treatment in idiopathic pulmonary fibrosis
Molina‐Molina, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2019.05.012 · Cited by 10
A modified scar model with controlled tension on secondary wound healing in mice
Wang, Z., Huang, X., Zan, T., Li, Q., & Li, H. (2020) · Burns & Trauma · doi:10.1093/burnst/tkaa013 · Cited by 11
“Compared to similar diseases, targeted therapies for scar progressed slowly (5, 6).”
BackgroundNintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Yamasaki, Y., & Kuwana, M. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1777857 · Cited by 8
“pirfenidone in patients with IPF were demonstrated in phase II [35] and phase III RCTs (CAPACITY [36] and ASCEND trials [37]).”
BackgroundTherapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis
Kim, S., Lim, J. H., & Woo, C.-H. (2020) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2020.00458 · Cited by 8
Biophysical and Epigenetic Regulation of Cancer Stemness, Invasiveness, and Immune Action
Veerasubramanian, P. K., Trinh, A., Akhtar, N., Liu, W. F., & Downing, T. L. (2020) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-020-00021-w · Cited by 9
Cottin, V., Bergot, E., BOURDIN, A. A., Nunès, H., Prévôt, G., Wallaert, B., & Marchand-Adam, S. (2021) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100811 · Cited by 9
Xia, F. F., Lu, F. A., Lv, H., et al. (2021) · PubMed · doi:10.19723/j.issn.1671-167x.2021.02.006 · Cited by 8
Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
Shebl, E., & Hamdy, T. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-021-00065-y · Cited by 8
Rheumatological evaluation of patients with interstitial lung disease
Ottaviani, S., Khaleche, S., Borie, R., Debray, M., Dieudé, P., & Crestani, B. (2021) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2021.1907945 · Cited by 9
Nishioka, Y., Homma, S. A., Okubo, T., & Azuma, A. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100832 · Cited by 9
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
Gorini, F., Santoro, M. C., Pierini, A., Mezzasalma, L., Baldacci, S., Bargagli, E., Boncristiano, A., Brunetto, M. R., Cameli, P., Cappelli, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869842 · Cited by 8
“Even though pirfenidone, an oral antifibrotic drug, is not capable of halting disease progression, it may reduce decline in lung function by inhibiting proliferation, myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts (Conte et al., 2014; King et al., 2014), resulting in a signific…”
BackgroundUpdates in Hypersensitivity Pneumonitis: A Narrative Review
Anwar, J., Kong, W. T., & Balakrishnan, B. (2022) · Current Pulmonology Reports · doi:10.1007/s13665-022-00294-6 · Cited by 11
A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
Moura, M. C., Branco, C., Martins-Martinho, J., Ferraro, J. L., Berti, A., Nogueira, E., & Ponte, C. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221125979 · Cited by 10
Progressive pulmonary fibrosis (PPF)
Duman, D. (2022) · Tuberkuloz ve Toraks · doi:10.5578/tt.20229609 · Cited by 10
Moodley, Y. P., Corte, T. J., Richeldi, L., & King, T. E. (2015) · Respirology · doi:10.1111/resp.12484 · Cited by 8
Self-citationOhkubo, H., Kunii, E., Moriyama, S., & Niimi, A. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.09.003 · Cited by 9
Idiopathic pulmonary fibrosis: combating on a new turf
Raghu, G. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30106-0 · Cited by 8
Hassoun, P. M., & Nathan, S. D. (2016) · European Respiratory Journal · doi:10.1183/13993003.00395-2016 · Cited by 8
Self-citationRepositioning compounds from cancer drug discovery to IPF: PI3K inhibition
Staab-Weijnitz, C. A., & Eickelberg, O. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-208680 · Cited by 9
Lung transplantation for high-risk patients with idiopathic pulmonary fibrosis.
Oliveira, N. C. D., Julliard, W. A., Osaki, S., Maloney, J. D., Cornwell, R. D., Sonetti, D. A., & Meyer, K. C. (2016) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 8
Improving Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.01.007 · Cited by 8
Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib
Hayton, C., & Chaudhuri, N. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17719126 · Cited by 10
Burgess, A., Goon, K., Brannan, J. D., Attia, J. R., Palazzi, K. L., Oldmeadow, C. J., Corte, T. J., Glaspole, I., Goh, N. S. L., Keir, G. J., et al. (2019) · Respirology · doi:10.1111/resp.13540 · Cited by 9
Self-citationBiologicals for severe asthma: what we can learn from real-life experiences?
Bagnasco, D., Caminati, M., & Passalacqua, G. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000600 · Cited by 8
“In fact, because of their short duration and experimental setting quite far from the daily clinical practice, RCTs did not provide extensive data concerning: long-term effects of omalizumab (safety and efficacy), especially after discontinuation; its impact on asthma comorbidities; adherence rate and reasons for drop-…”
ResultInfluentialMura, M. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101987 · Cited by 8
George, P. M., & Wells, A. U. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1427064 · Cited by 9
Actualités dans les pneumopathies interstitielles idiopathiques en 2016
Debray, M., Borie, R., Danel, C. J., Khalil, A., Majlath, M., & Crestani, B. (2016) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2016.09.001 · Cited by 8
Getting to the core of fibrosis: targeting redox imbalance in aging
Hecker, L., & Thannickal, V. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2015.12.45 · Cited by 8
Bouros, D., Daniil, Z., Papakosta, D., Antoniou, K. M., Markopoulou, K., Kolilekas, L., Konstantopoulos, G., Papiris, S., & on behalf of the INDULGE IPF Study Group (2018) · Respiration · doi:10.1159/000487244 · Cited by 7
Zhang, X.-L., Cao, Y., & Zheng, B. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02778-w · Cited by 7
Sunitinib displays pulmonary fibrosis in experimental rats: Role of IL-17A dependent pathway
Asker, M. E.-S., Abdelmeged, A. A., Shaheen, M. A., & Eissa, R. G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110173 · Cited by 6
Lu, X. Y., Zhu, C., Gao, Y., Yu, Z., Yan, Q., Liu, Y., Luo, M., & Shi, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107018 · Cited by 8
The Association between Dyslipidemia and Pulmonary Diseases
Isago, H. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22021 · Cited by 11
Chong, W. H., Agrawal, D., Tan, Z. Y., Venkateswaran, S., Tan, A. Y. Y., Tan, C. Y., Ling, N. C. A., & Tay, N. S. W. T. (2024) · Heart & Lung · doi:10.1016/j.hrtlng.2024.07.010 · Cited by 7
Walker, A. M., Sullivan, D. R., Nguyen, P., Holland, A. E., & Smallwood, N. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241305497 · Cited by 11
Kette, S., Reccardini, N., Salton, F., Confalonieri, P., Andrisano, A. G., Chianese, M. I., Nes, A. D., Maggisano, M., Galantino, A., Nicolosi, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030411 · Cited by 8
“Despite these outcomes, several side effects have been reported [16,19,47].”
InfluentialOkuno, D., Akiyama, Y., Sakamoto, N., Tokito, T., Yura, H., Kido, T., Ishimoto, H., Ishimatsu, Y., Takemoto, S., Takazono, T., et al. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114584 · Cited by 9
Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution
Fortier, S. M., Redente, E. F., & Peters-Golden, M. L. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2666-7479 · Cited by 11
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.